AestheticsFeatured Articles

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

By August 25, 2020No Comments

Featured Article

Featured Article

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Read more

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.

This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.

This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD featuring Dr. Jacob Beer in JDD Re:View, a discussion of JDD articles and specific topics. This article highlights Aesthetics Is Changing. Here’s What We’re Seeing?

JDD Re:View With Dr. Beer

| Aesthetics, Alopecia, Featured Articles, Hair, JDD Re:View, Latest News | No Comments
Hair Disorders and Treatments   Hair treatments have proliferated in the past several years. While prior treatment options were limited to topical minoxidil and oral finasteride for androgenetic alopecia (AGA),…

Proximal Subungual Onychomycosis in the Immunocompetent: A Case Report and Review of the Literature

| Featured Articles, Latest News, Nails | No Comments
From the Vault: Pulled due to increased interest in rare onychomycosis presentations This case report dates back to JDD’s April 2018 issue. It’s a case report describing a healthy 51-year-old…
Journal of Drugs in Dermatology JDD Article about Brodalumab’s 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence

Brodalumab’s 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence

| Featured Articles, Latest News, Psoriasis | No Comments
Updated long term and real world evidence on efficacy and safety This is a must-read JDD article on brodalumab in plaque psoriasis. The review summarizes long term clinical trial findings,…

Leave a Reply